This result was also observed in apoptosis assays using flow cytometry (Fig. S5B), suggesting that SMARCD1 knockdown may affect the proliferative capacity of GEM‐R BC cell lines by other mechanisms and may be involved in the sensitivity to gemcitabine. Here, SMARCD1 is linked to breast cancer.